John Pappajohn, Director at CANCER GENETICS, INC (CGIX), bought 1,000,000 shares at $0.23 ($230K) on 2019-01-31, disclosed to the SEC on 2019-02-01.
Open-market purchase of $230k CGIX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| CGIX | BUY | 2019-01-16 | $230K | — | Filing → |
| MYND | BUY | 2018-08-28 | $163K | — | Filing → |
| CGIX | BUY | 2017-12-11 | $279K | — | Filing → |